Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients

American Journal of Pathology

Volumn 155, Issue 2, 1999, Pages 537-547

  Bellone, Graziella ^a   Turletti, Anna ^a   Artusio, Elisa ^a   Mareschi, Katia ^a   Carbone, Anna ^a   Tibaudi, Daniela ^a   Robecchi, Antonio ^a   Emanuelli, Giorgio ^a   Rodeck, Ulrich ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MONONUCLEAR CELL; PANCREAS CARCINOMA; PRIORITY JOURNAL;

EID: 0032770957     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65149-8     Document Type: Article

References (64)

1. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176:1453-1457
2. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994, 91:3515-3519
3. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH, Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994, 24:759-764
4. Sulitzeanu D: Immunosuppressive factors in human cancer. Adv Cancer Res 1993, 60:247-267
5. Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol 1990, 6:597-641
6. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987, 47:707-712
7. Baldwin RL, Friess H, Yokoyama M, Lopez ME, Kobrin MS, Buchler MW, Korc M: Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996, 67:283-288
8. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival, Gastroenterology 1993, 105:1846-1856
9. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 1992, 52:6949-6952
10. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A: Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992, 148:1404-1410
11. Jennings MT, Maciunas RJ, Carver R, Bascom CC, Juneau P, Misulis K, Moses HL: TGF beta 1 and TGF beta 2 are potential growth regulators for low grade and malignant gliomas in vitro: evidence in support of an autocrine hypotesis. Int J Cancer 1991, 49:129-139
12. Olofsson A, Miyazono K, Kanzaki T, Colosetti P. Engstrom U, Heldin CH: Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J Biol Chem 1992, 267:19482-19488
13. Albino AP, Davis BM, Nanus DM: Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res 1991, 51:4815-4820
14. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M: Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 1991, 97:20-26
15. Rodeck U, Bossler A, Graeven U, Fox F, Nowell P, Kari C: Transforming growth factor-beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 1994, 54:575-581
16. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA: A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990, 87:1486-1490
17. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996, 93:2909-2914
18. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT: Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993, 92:2569-2576
19. Wrann M, Bodmer S, de Martin R, Siepl C. Hofer Warbinck R, Frei J, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J 1987, 6:1633-1636
20. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G: Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 1993, 36:409-416
21. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 1993, 11:165-190
22. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993, 151:1224-1234
23. Fernandez-Botran R, Sanders VM, Mosmann TR, Vitetta ES: Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med 1988, 168:543-558
24. Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081-2095
25. Hsu DH, Moore KW, Spits H: Differential effects of IL-4 and IL-10 on IL2-induced IFN-gamma synthesis and lymphokine-activated killer activity. Int J Immunol 1992, 4:563-569
26. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993, 55:96-101
27. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura R, Modlin R, Wollman J, Dubinett SM: Human non-small-cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995, 55:3847-3851
28. Kruger-Krasagakis S, Krasagakis K, Garbe C, Diamantstein T: Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res 1995, 139:155-168
29. Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D: Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 1995, 41:151-156
30. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocke EB: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995, 5:67-68
31. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 1992, 326:455-465
32. Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valante G, Emanuelli G, Rodeck U: Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol 1997, 172:1-11
33. Behringer DM, Sunderer B, Andersson U, Kresin V, Mertelsmann R, Lindemann A: Simultaneous detection of cytokine and immunophenotype at the single cell level by immunoenzymatic double staining. Histochem J 1996, 28:461-466
34. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U: Regulation of NK cell functions by TGF-beta 1. J Immunol 1995, 155:1066-1073
35. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste-Amezaga M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolfe SF, Trinchieri G: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992, 176:13871-13898
36. Siepl C, Bodmer S, Frei K, Mac Donald HR, De Martin R, Hofer E, Fontana A: The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 1988, 18:593-600
37. Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, McKean DJ, Abraham RT: Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol 1990, 144:1767-1776
38. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986, 163:1037-1050
39. Roussel F, Garcia E, Defrance T, Peonne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J: Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992, 89:1890-1893
40. de Waal Malefyt R, Yssel H, de Vries JE: Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells specific inhibition of IL-2 production and proliferation. J Immunol 1993, 150: 4754-4765
41. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS: Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986, 136:3916-3920
42. Liew FY: Induction and regulation of CD4+ T cell subsets. Ciba Found Symp 1994, 187:170-175
43. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P: IL-12 is requited for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995, 154:5320-5330
44. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991, 146:3444-3451
45. Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rude E, Germann T: T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol 1994, 24:793-798
46. Maeda H, Shiraishi A TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice J Immunol 1996, 156:73-78
47. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL: Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995, 222:155-162
48. Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di Pierro F, De Giovanni C, Musso T, Forni G: Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995, 155:3112-3123
49. Kundu N, Beaty TL, Jackson MJ, Fulton AM: Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996, 88:536-541
50. Ishizaka S, Yoshikawa M, Tsujii T: Immunoregulatory effects of transforming growth factor-beta in a prolonged period of culture. Cell Immunol 1992, 139:239-247
51. Kasid A, Bell GI, Director EP: Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 1988, 141:690-698
52. Fox FE, Ford HC, Douglas R, Cherian S, Nowell PC: Evidence that TGF-beta can inhibit human T-lymphocyte proliferation through paracrine and autocrine mechanisms. Cell Immunol 1993, 150:45-58
53. Kehrl JH, Taylor AS, Delsing GA, Roberts AB, Sporn MB, Fauci AS: Further studies of the role of transforming growth factor-beta in human B cell function. J Immunol 1989, 143:1868-1874
54. Lee HM, Rich S: Co-stimulation of T cell proliferation by transforming growth factor-beta 1. J Immunol 1991, 147:1127-1133
55. Itoh K, Hirohata S: The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 1995, 154:4341-4350
56. Huang M, Sharma S, Mao JT, Dubinett SM: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996, 157:5512-5520
57. Katamura K, Shintaku N, Yamauchi Y Fukui T, Ohshima Y, Mayumi M, Furusho K: Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J Immunol 1995, 155:4604-4612
58. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU: Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996, 42:1-8
59. Yamamura M, Modlin RL, Ohmen JD, Moy RL: Local expression of antiinflammatory cytokines in cancer. J Clin Invest 1993, 91:1005-1010
60. Tahara H, Zeh HJ, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT: Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994, 54:182-189
61. Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Cavallo F, Di Pierro F, Novelli F, Forni G: An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994, 153:5659-5673
62. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev lmmunol 1995, 13:399-415
63. Rodolfo M, Zilocchi C. Melani C, Capetti B, Arioli I, Parmiani G, Colombo MP: Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 1996, 157:5536-5542
64. Apostolopoulos V, Xing PX, McKenzie IF: Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens Cancer Res 1994, 54:5186-5193